

Effective date: Nov. 1, 2025

Applies to:

Commercial Products

- Harvard Pilgrim Health Care Commercial products
- Tufts Health Plan Commercial products

Public Plans Products

- Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product)
- Tufts Health Together – MassHealth Accountable Care Partnership Plans
- Tufts Health RITogether – A Rhode Island Medicaid Plan
- Tufts Health One Care – A dual-eligible product

Senior Products

- Tufts Health Plan Senior Care Options (SCO) (a dual-eligible product)
- Tufts Medicare Preferred HMO/PPO (Medicare Advantage products)

Policy

Systemic autoimmune rheumatic diseases (SARDs) are a diverse group of conditions that primarily affect the joints, bones, muscle, and connective tissue. SARDs are characterized by dysregulated immunity and inflammatory responses, resulting in damage and destruction to joints, connective tissues, skin, blood elements, and other target organs; however, considerable diversity in clinical presentation, disease course, and treatment response exists.

The diagnostic workup for SARDs may involve the antinuclear antibody (ANA) assay, which is used to detect autoantibodies (AAB) against intracellular antigens, originally known as antinuclear antibodies. Commonly used as part of the initial diagnostic workup to screen for evidence of systemic autoimmunity, detection and identification of AABs are important in the diagnosis of SARDs, such as systemic lupus erythematosus (SLE), Sjögren's syndrome (SjS), mixed connective tissue disease (MCTD), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIMs). Extractable nuclear antigens or ENAs (a historical term from when the antigens were extracted from the cell into saline solution prior to testing) include Sm, U1 ribonucleoprotein (RNP), Ro, and La antigens, and are also useful for evaluating individuals with suspected connective tissue disease.

Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

1. For individuals with signs or symptoms of an autoimmune disease, screening for disease using antinuclear antibodies (ANA) **MEETS COVERAGE CRITERIA:**
 - a. Once during initial workup.
 - b. Up to two additional tests per lifetime if new or more severe signs or symptoms of an autoimmune disease develop.
2. For individuals with an abnormal, raised ANA titer and a clinical correlation with the appropriate autoimmune disorder, extractable nuclear antigens (ENA) panel testing of specific autoantibodies **MEETS COVERAGE CRITERIA.**
3. For individuals with painful and swollen joints suggestive of rheumatoid arthritis (RA), testing for rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies **MEETS COVERAGE CRITERIA:**
 - a. Once during initial workup.
 - b. If initial testing did not result in a diagnosis of RA, up to two additional tests per lifetime if symptoms persist or additional symptoms of RA develop.
4. For individuals with an initial positive ANA test and a diagnosis of systemic autoimmune rheumatic disease, testing of dsDNA up to four (4) times per year **MEETS COVERAGE CRITERIA.**
5. For individuals with a negative or low positive ANA test, the following condition specific antibody testing **MEETS COVERAGE CRITERIA:**
 - a. Testing for anti-Jo-1 in a unique clinical subset of myositis.
 - b. Testing for anti-SSA in the setting of lupus or Sjögren's syndrome.

6. Monitoring of disease with ANA testing or ANA titers **DOES NOT MEET COVERAGE CRITERIA.**
7. For individuals without symptoms suggestive of an autoimmune disorder, ANA and/or ENA testing **DOES NOT MEET COVERAGE CRITERIA.**
8. For all other situations not described above, testing of specific antibodies in the absence of a positive ANA test **DOES NOT MEET COVERAGE CRITERIA.**
9. For asymptomatic individuals, testing of ANA and/or ENA during a wellness visit or a general exam without abnormal findings **DOES NOT MEET COVERAGE CRITERIA.**

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

10. For the diagnosis of RA, testing for serum biomarkers not discussed above, alone or in a panel (e.g., Seronegative Rheumatoid Arthritis Profile), **DOES NOT MEET COVERAGE CRITERIA.**
11. ~~For the management of RA, Serum biomarker panel testing~~ designed to manage RA (e.g., Vectra ~~DA score~~, PrismRA) **DOES NOT MEET COVERAGE CRITERIA.**
12. ~~For the diagnosis of systemic lupus erythematosus (SLE), the use of C~~cell-bound complement activation products (e.g., AVISE Lupus) designed to diagnose, prognose, or monitor systemic lupus erythematosus (SLE) ~~DOES NOT MEET COVERAGE CRITERIA.~~
13. ~~For the diagnosis, prognosis, or monitoring of Serum biomarker panel testing (with or without proprietary algorithms and/or index scores) that is designed to diagnose, prognose, or monitor SLE or connective tissue diseases, serum biomarker panel testing with proprietary algorithms and/or index scores~~ (e.g., AVISE CTD, AVISE SLE Monitor, AVISE SLE Prognostic, aisle® DX Disease Activity Index, Early Sjögren's Syndrome Profile) Tissue Specific Markers for Early Diagnosis of Sjögren's Disease **DOES NOT MEET COVERAGE CRITERIA.**

Applicable CPT/HCPCS Procedure Codes

Procedure codes appearing in policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Coding

Code	Description
81490	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score Proprietary test: Vectra® DA Lab/Manufacturer: Crescendo Bioscience, Inc. Labcorp
81599	Unlisted multianalyte assay with algorithmic analysis
86038	Antinuclear antibodies (ANA)
86039	Antinuclear antibodies (ANA); titer
86200	Cyclic citrullinated peptide (CCP), antibody
86225	Deoxyribonucleic acid (DNA) antibody; native or double stranded
86235	Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody
86430	Rheumatoid factor; qualitative
86431	Rheumatoid factor; quantitative
0062U	"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score Proprietary test: SLE-key® Rule Out Lab/Manufacturer: Veracis Inc"
0312U	"Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment Proprietary test: Avise® Lupus Lab/Manufacturer: Exagen Inc"
0446U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity Proprietary test: aisle® DX Disease Activity Index

Code	Description
	Lab/Manufacturer: Progenotes Diagnostics, Inc
0447U	Autoimmune diseases (systemic lupus erythematosus [sle]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare Proprietary test: aisle® DX Disease Activity Index Lab/Manufacturer: Progenotes Diagnostics, Inc
0521U	Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood Proprietary test: Seronegative Rheumatoid Arthritis Panel Lab Manufacturer: KSL Diagnostics-Beutner Laboratories, Inc, KSL Biomedical, Inc
<u>0522U</u>	<u>Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiquantitative, blood</u> <u>Proprietary test: Tissue Specific Markers for Early Diagnosis of Sjögren's Disease</u> <u>Lab Manufacturer: KSL Diagnostics, Inc, KSL Diagnostics, Inc (Effective for DOS beginning 9/1/2026)</u>

Evidence-based Scientific References

1. AAFP. Autoimmune Rheumatic Diseases. Updated April 2019. https://www.aafp.org/dam/AAFP/images/about-us/content/Quest_SH8265_SoH_Autoimmune%20Rheumatic%20Diseases_HealthcareProviders_April_FINAL-2.pdf
2. Guthridge JM, Wagner CA, James JA. The promise of precision medicine in rheumatology. *Nat Med.* Jul 2022;28(7):1363-1371. doi:10.1038/s41591-022-01880-6
3. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. *Advances in immunology.* 1989;44:93-151.
4. Satoh M, Chan EK, Sobel ES, et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. *Expert review of clinical immunology.* Sep 2014;3(5):721-38. doi:10.1586/1744666x.3.5.721
5. Tebo AE. Recent Approaches To Optimize Laboratory Assessment of Antinuclear Antibodies. *Clinical and vaccine immunology : CVI.* Dec 2017;24(12)doi:10.1128/cvi.00270-17
6. Bloch D. Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP. Updated October 24, 2025. <https://www.uptodate.com/contents/antibodies-to-double-stranded-ds-dna-sm-and-u1-rnp>
7. Global Autoimmune Institute. The Global Landscape of Autoimmune Disease. Updated February 20, 2024. <https://www.autoimmuneinstitute.org/articles/the-global-landscape-of-autoimmune-disease/>
8. Simon TA, Kawabata H, Ray N, Baheti A, Suissa S, Esdaile JM. Prevalence of Co-existing Autoimmune Disease in Rheumatoid Arthritis: A Cross-Sectional Study. *Advances in therapy.* Nov 2017;34(11):2481-2490. doi:10.1007/s12325-017-0627-3
9. CDC. People with Lupus. Updated May 15, 2024. <https://www.cdc.gov/lupus/data-research/index.html>
10. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. *Rheumatology (Oxford).* Nov 1 2017;56(11):1945-1961. doi:10.1093/rheumatology/kex260
11. Zucchi D, Elefante E, Calabresi E, Signorini V, Bortoluzzi A, Tani C. One year in review 2019: systemic lupus erythematosus. *Clin Exp Rheumatol.* Sep-Oct 2019;37(5):715-722.
12. Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. *Lancet.* Jun 8 2019;393(10188):2332-2343. doi:10.1016/s0140-6736(19)30237-5
13. Finzel S, Schaffer S, Rizzi M, Voll RE. [Pathogenesis of systemic lupus erythematosus]. *Z Rheumatol.* Nov 2018;77(9):789-798. Pathogenese des systemischen Lupus erythematosus. doi:10.1007/s00393-018-0541-3
14. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. *J Autoimmun.* Jan 2019;96:1-13. doi:10.1016/j.jaut.2018.11.001
15. Thong B, Olsen NJ. Systemic lupus erythematosus diagnosis and management. *Rheumatology (Oxford).* Apr 1 2017;56(suppl_1):i3-i13. doi:10.1093/rheumatology/kew401
16. Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. *Clin Rheumatol.* Nov 2019;38(11):2967-2976. doi:10.1007/s10067-019-04684-1
17. Luan H, Gu W, Li H, et al. Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients. *J Transl Med.* Dec 7 2021;19(1):500. doi:10.1186/s12967-021-03169-7
18. Pappas DA, St John G, Etzel CJ, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. *Ann Rheum Dis.* Jan 2021;80(1):96-102. doi:10.1136/annrheumdis-2020-217209

19. Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. *J Autoimmun.* Jun 2020;110:102400. doi:10.1016/j.jaut.2019.102400
20. Cohen S, Wells AF, Curtis JR, et al. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- α Inhibitors: The NETWORK-004 Prospective Observational Study. *Rheumatol Ther.* Sep 2021;8(3):1159-1176. doi:10.1007/s40744-021-00330-y
21. Baker JF. Diagnosis and differential diagnosis of rheumatoid arthritis. Updated March 21, 2024. <https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-rheumatoid-arthritis>
22. McArdle A, Flatley B, Pennington SR, FitzGerald O. Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. *Arthritis Res Ther.* Jun 1 2015;17(1):141. doi:10.1186/s13075-015-0652-z
23. Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. *Arthritis Care Res (Hoboken).* Dec 2012;64(12):1794-803. doi:10.1002/acr.21767
24. Centola M, Cavet G, Shen Y, et al. Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. *PLoS One.* 2013;8(4)doi:10.1371/journal.pone.0060635
25. Shmerling R. Biologic markers in the assessment of rheumatoid arthritis. Updated October 13, 2025. <https://www.uptodate.com/contents/biologic-markers-in-the-assessment-of-rheumatoid-arthritis>
26. Shapiro SC. Biomarkers in Rheumatoid Arthritis. *Cureus.* May 16 2021;13(5):e15063. doi:10.7759/cureus.15063
27. Castro CTd, Queiroz MJd, Albuquerque FC, et al. Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis. *Systematic Review. Frontiers in Pharmacology.* 2022-August-11 2022;13doi:10.3389/fphar.2022.927179
28. Bergman MJ, Kivitz AJ, Pappas DA, et al. Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. *Rheumatol Ther.* Dec 2020;7(4):775-792. doi:10.1007/s40744-020-00226-3
29. Curtis JR, Schabert VF, Harrison DJ, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. *Clin Ther.* Jul 1 2014;36(7):996-1004. doi:10.1016/j.clinthera.2014.05.062
30. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. *J Clin Invest.* 2015;125(6):2194-202. doi:10.1172/jci78084
31. Aggarwal A. Role of autoantibody testing. *Best practice & research Clinical rheumatology.* Dec 2014;28(6):907-20. doi:10.1016/j.berh.2015.04.010
32. Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. *Autoimmunity reviews.* Jun 2015;14(6):555-63. doi:10.1016/j.autrev.2015.01.017
33. Selmi C, Ceribelli A, Generali E, et al. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. *Autoimmunity reviews.* Feb 2016;15(2):162-6. doi:10.1016/j.autrev.2015.10.007
34. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; the tart cell and the L.E. cell. *Proceedings of the staff meetings Mayo Clinic.* Jan 21 1948;23(2):25-8.
35. ACR. Position Statement on Methodology of Testing for Antinuclear Antibodies. *American College Of Rheumatology;* 2015. <https://primexlab.com/wp-content/uploads/2016/10/Methodology-of-Testing-Antinuclear-Antibodies-Position-Statement.pdf>
36. Chan EK, Damoiseaux J, de Melo Cruvinel W, et al. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. *Lupus.* Jul 2016;25(8):797-804. doi:10.1177/0961203316640920
37. Bloch D. Measurement and clinical significance of antinuclear antibodies. Updated September 05, 2025. <https://www.uptodate.com/contents/measurement-and-clinical-significance-of-antinuclear-antibodies>
38. Yoo IY, Oh JW, Cha HS, Koh EM, Kang ES. Performance of an Automated Fluorescence Antinuclear Antibody Image Analyzer. *Annals of laboratory medicine.* May 2017;37(3):240-247. doi:10.3343/alm.2017.37.3.240
39. Yang H, Ray LE. Antinuclear Antibodies (ANA). Updated February 2025. <https://rheumatology.org/patients/antinuclear-antibodies-ana>
40. Wallace DJ, Gladman D. Systemic lupus erythematosus in adults: Clinical manifestations and diagnosis. Updated February 12, 2025. <https://www.uptodate.com/contents/systemic-lupus-erythematosus-in-adults-clinical-manifestations-and-diagnosis>
41. Tonutti E, Bizzaro N, Morozzi G, et al. The ANA-reflex test as a model for improving clinical appropriateness in autoimmune diagnostics. *Auto Immun Highlights.* 2016;7(1)doi:10.1007/s13317-016-0080-3
42. AVISE. AVISE Testing Exclusively from Exagen Inc. <https://avisetest.com/provider/>
43. Exagen. AVISE Lupus. <https://exagen.com/tests/lupus/>
44. van der Helm-van Mil AHM, Knevel R, Cavet G, Huizinga TWJ, Haney DJ. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. *Rheumatology (Oxford).* 2013;839-46. vol. 5.
45. Progenotes Diagnostics Inc. aiSLE DX. <https://www.progentec.com/aisle-dx>
46. KSL Diagnostics-Beutner. Seronegative Rheumatoid Arthritis Profile. <https://www.beutnerlabs.com/rheumatoid-arthritis-ra-laboratory-testing>
47. Immco Diagnostics. Sjo. <https://www.immco.com/wp-content/uploads/2018/09/ML-111-Sjogren-Syndrome-Flyer-0818-Rev.pdf>
48. van der Pol P, Bakker-Jonges LE, Kuijpers J, Schreurs MWJ. Analytical and clinical comparison of two fully automated immunoassay systems for the detection of autoantibodies to extractable nuclear antigens. *Clinica chimica acta; international journal of clinical chemistry.* Jan 2018;476:154-159. doi:10.1016/j.cca.2017.11.014

49. Tipu HN, Bashir MM. Determination of Specificity and Pattern of Antinuclear Antibodies (ANA) in Systemic Rheumatic Disease Patients Positive for ANA Testing. *J Coll Physicians Surg Pak.* Jan 2018;28(1):40-43.
50. Kim J, Lee W, Kim GT, et al. Diagnostic utility of automated indirect immunofluorescence compared to manual indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. *Seminars in arthritis and rheumatism.* Feb 2019;48(4):728-735. doi:10.1016/j.semarthrit.2018.03.015
51. Dervieux T, Conklin J, Ligayon JA, et al. Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. *J Immunol Methods.* Jul 2017;446:54-59. doi:10.1016/j.jim.2017.04.001
52. Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. *Lupus Sci Med.* 2014;1(1):e000056. doi:10.1136/lupus-2014-000056
53. Ramsey-Goldman R, Alexander RV, Massarotti EM, et al. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. *Arthritis Rheumatol.* Jan 2020;72(1):78-88. doi:10.1002/art.41093
54. Oglesby A, Korves C, Laliberté F, et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. *Appl Health Econ Health Policy.* Apr 2014;12(2):179-90. doi:10.1007/s40258-014-0085-x
55. Yeo AL, Le S, Ong J, et al. Utility of repeated antinuclear antibody tests: a retrospective database study. *The Lancet Rheumatology.* 2020/07/01/ 2020;2(7):e412-e417. doi:10.1016/S2665-9913(20)30084-9
56. Deng X, Peters B, Ettore MW, et al. Utility of Antinuclear Antibody Screening by Various Methods in a Clinical Laboratory Patient Cohort. *J Appl Lab Med.* Jul 1 2016;1(1):36-46. doi:10.1373/jalm.2016.020172
57. Alsaed OS, Alamlh LI, Al-Radideh O, Chandra P, Alemadi S, Al-Allaf AW. Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases. *Sci Rep.* Apr 15 2021;11(1):8229. doi:10.1038/s41598-021-87366-w
58. Wallace DJ, Alexander RV, O'Malley T, et al. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. *Lupus science & medicine.* 2019;6(1):e000349. doi:10.1136/lupus-2019-000349
59. Mossell J, Goldman JA, Barken D, Alexander RV. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. *Open Rheumatol J.* 2016;10:71-80. doi:10.2174/1874312901610010071
60. Liang E, Taylor M, McMahan M. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. *Lupus Science & Medicine.* 2020;7(1):e000345. doi:10.1136/lupus-2019-000345
61. Alexander RV, Rey DS, Conklin J, et al. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. *Lupus Sci Med.* Jul 2021;8(1)doi:10.1136/lupus-2021-000528
62. Clarke AE, Weinstein A, Piscitello A, et al. Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP). *ACR Open Rheumatology.* 2020;n/a(n/a)doi:10.1002/acr2.11177
63. Mellors T, Withers JB, Ameli A, et al. Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients. *Network and Systems Medicine.* July 14, 2020 2020;3(1):91-104. doi:10.1089/nsm.2020.0007
64. Hirata S, Dirven L, Shen Y, et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. *Rheumatology (Oxford).* Jul 2013;52(7):1202-7. doi:10.1093/rheumatology/kes362
65. Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. *Ann Rheum Dis.* Oct 2012;71(10):1692-7. doi:10.1136/annrheumdis-2011-200963
66. Li W, Sasso EH, Emerling D, Cavet G, Ford K. Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. *Current medical research and opinion.* Jan 2013;29(1):85-92. doi:10.1185/03007995.2012.753042
67. Li W, Sasso EH, van der Helm-van Mil AH, Huizinga TW. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. *Rheumatology (Oxford).* Feb 2016;55(2):357-66. doi:10.1093/rheumatology/kev341
68. Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL. Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. *Seminars in arthritis and rheumatism.* Feb 2018;47(4):472-477. doi:10.1016/j.semarthrit.2017.07.010
69. Curtis JR, Flake DD, Weinblatt ME, et al. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. *Rheumatology (Oxford).* May 1 2019;58(5):874-883. doi:10.1093/rheumatology/key367
70. Brahe CH, Ostergaard M, Johansen JS, et al. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. *Scand J Rheumatol.* Jan 2019;48(1):9-16. doi:10.1080/03009742.2018.1464206
71. Ma MHY, Defranoux N, Li W, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. *Arthritis Research & Therapy.* 2020/06/24 2020;22(1):158. doi:10.1186/s13075-020-02240-w
72. Curtis JR, Weinblatt ME, Shadick NA, et al. Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. *Arthritis Research & Therapy.* 2021/01/04 2021;23(1):1. doi:10.1186/s13075-020-02389-4

73. Fleischmann R, Liu J, Zhu J, Segurado OG, Furst DE. Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. Sep 2022;74(9):1477-1483. doi:10.1002/acr.24583
74. Sammaritano LM, Anca Askanase, MD, MPH, Bonnie L. Bermas, MD, Maria Dall'Era, MD, Alí Duarte-García, MD, MSc, Linda T. Hiraki, MD, MSc, ScD, Mary Beth F. Son, MD, Victoria P. Werth, MD., Cynthia Aranow M, April Barnado, MD, MSCI, Anna Broder, MD, MSc., Hermine I. Brunner M, MSc, MBA, Benjamin F. Chong, MD, MSCS., et al. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. *American College of Rheumatology*. 2025;doi:10.1002/acr.25690
75. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. Sep 1997;40(9):1725. doi:10.1002/art.1780400928
76. CDC. Lupus Basics. Updated May 15, 2024. <https://www.cdc.gov/lupus/about/index.html>
77. Mosca M, Costenbader KH, Johnson SR, et al. Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. *Arthritis Rheumatol*. Jan 2019;71(1):91-98. doi:10.1002/art.40674
78. ACR. 1997 Update of the 1982 American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus. <https://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201982%20Revised.pdf>
79. ACR. Policy & Position Statements. <https://rheumatology.org/policy-position-statements>
80. Yazdany J, Schmajak G, Robbins M, et al. Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should question. *Arthritis Care & Research*. 2013;65(3):329-339. doi:10.1002/acr.21930
81. Rouster-Stevens KA, Ardoin SP, Cooper AM, et al. Choosing Wisely: the American College of Rheumatology's Top 5 for pediatric rheumatology. *Arthritis Care Res (Hoboken)*. May 2014;66(5):649-57. doi:10.1002/acr.22238
82. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. Jul 2021;73(7):924-939. doi:10.1002/acr.24596
83. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis*. Sep 2019;78(9):1151-1159. doi:10.1136/annrheumdis-2018-214819
84. Josef SS, Robert BML, Sytske Anne B, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Annals of the Rheumatic Diseases*. 2023;82(1):3. doi:10.1136/ard-2022-223356
85. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. Aug 2012;64(8):2677-86. doi:10.1002/art.34473
86. British Columbia Rheumatoid Arthritis. Diagnosis, Management and Monitoring Guideline. <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/rheumatoid-arthritis>
87. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M. Management of rheumatoid arthritis: summary of NICE guidance. *Bmj*. Mar 16 2009;338:b702. doi:10.1136/bmj.b702
88. RACGP. Recommendations for the diagnosis and management of early rheumatoid arthritis. <https://www.racgp.org.au/FSDEDEV/media/documents/Clinical%20Resources/Guidelines/Joint%20replacement/Rheumatoid-arthritis-recommendations.pdf>

Publication History

- 07/01/2026:** [Annual policy review; administrative edits; added code 0522U effective for DOS beginning Sept. 1, 2026](#)
- 09/01/2025:** Policy created to support coverage guidelines, effective for dates of service beginning Nov. 1, 2025
-

Background and Disclaimer Information

This policy applies to the products of Harvard Pilgrim Health Care and Tufts Health Plan and their affiliates, as identified in the check boxes on the first page for services performed by contracted providers.

Payment is based on member benefits and eligibility on the date of service, medical necessity review, where applicable, and the provider's network participation agreement with the Plan. As every claim is unique, this policy is neither a guarantee of payment, nor a final indication of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization, and utilization management requirements (when applicable), adherence to Plan policies and procedures, and claims editing logic. An authorization is not a guarantee of payment.

Point32Health reserves the right to amend a payment policy at its discretion. CPT and HCPCS codes are updated as applicable; please adhere to the most recent CPT and HCPCS coding guidelines.

We reserve the right to conduct audits on any provider and/or facility to ensure accuracy and compliance with the guidelines stated in this payment policy. If such an audit determines that a provider/facility did not comply with this payment policy, Harvard Pilgrim Health Care and Tufts Health Plan will expect the provider/facility to refund all payments related to noncompliance.